Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth

1 month ago 21

Ricardo Pillai

Mon, July 27, 2026 astatine 7:41 AM CDT 3 min read

Jensen Investment Management, an plus absorption institution based successful the US, released its second-quarter 2026 capitalist missive for the "Jensen Quality Growth Equity Strategy". A transcript of the missive is disposable to download here. The money seeks semipermanent maturation by investing successful high-quality companies with durable competitory advantages. It returned 10.94% nett of fees successful Q2 2026, trailing the 15.20% instrumentality for the S&P 500 Index. US equities posted their strongest 4th successful astir six years arsenic easing Iran-related tensions, improving fiscal conditions, resilient user spending, and continued AI infrastructure concern lifted markets. AI and memory-related semiconductor stocks led the rally, portion lower-quality and momentum stocks outperformed the prime factors cardinal to Jensen's strategy. Quarterly show benefited from favorable banal enactment successful Communication Services and nary vulnerability to Energy and Utilities, portion enactment successful Industrials and Information Technology wounded comparative returns. The Portfolio remains balanced crossed prime compounders, AI beneficiaries, and antiaircraft businesses. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Jensen Quality Growth Equity Strategy highlighted Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells wellness attraction products worldwide. On July 24, 2026, Abbott Laboratories (NYSE:ABT) closed astatine $103.06 per share. One-month instrumentality of Abbott Laboratories (NYSE:ABT) was 7.04%, and its shares mislaid 18.43% implicit the past 52 weeks. Abbott Laboratories (NYSE:ABT) has a marketplace capitalization of astir $179.51 billion, with a 52-week trading scope betwixt $81.97 - $137.49.

Jensen Quality Growth Equity Strategy stated the pursuing regarding Abbott Laboratories (NYSE:ABT) successful its Q2 2026 capitalist letter:

"Abbott Laboratories (NYSE:ABT) detracted from show during the 4th pursuing adecline successful the banal terms aft Q1 earnings. Management lowered full-year guidance to bespeak dilution from the Exact Sciences acquisition, portion prime businesses, including Nutrition and portions of Diagnostics, experienced near-term headwinds. The banal was besides pressured by ongoing uncertainty surrounding NEC litigation related to its preterm babe formula, which continues to measurement connected capitalist sentiment. These headwinds overshadowed different beardown results, led by high-single-digit integrated maturation successful some Medical Devices and Established Pharma segments, which unneurotic correspond implicit 62% of Q1 sales."

Read Entire Article